Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $265,370 - CYTK News | RalliesCytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $265,370
C
CYTK• Insider stock sale and option exercise
- Malik Fady Ibraham, EVP Research & Development at Cytokinetics, exercised stock options for 3,500 shares on Aug. 18, 2026 at USD 7.8.
- Same day sale of 3,500 shares at USD 75.82; direct holdings fell to 153,902 shares.
- Non-Qualified Stock Option (Right to Buy) balance declined to 30,386 options, exercisable through Feb. 27, 2028.
EAD
•
